Kontafarma Reports Shift to Loss in 2024 Interim Results

Kontafarma China Holdings Ltd (HK:1312) has released an update.

Kontafarma China Holdings Ltd reported its unaudited interim financial results, revealing a shift from a profit of HK$21,378,000 for the first half of 2023 to a loss of HK$4,532,000 in the same period of 2024. The results showed a slight increase in revenue but were impacted by significant other gains and losses, along with a decrease in gross profit. Total comprehensive income also swung to a loss, reflecting challenges the company faced over the past six months.

For further insights into HK:1312 stock, check out TipRanks’ Stock Analysis page.